We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gut Microbiome Data Helps Routine Screening of Cardiovascular Disease

By LabMedica International staff writers
Posted on 22 Sep 2020
Besides genetics and environmental factors, gut microbiota has emerged as a new factor influencing cardiovascular disease (CVD). More...
Although cause-effect relationships are not clearly established, the reported associations between alterations in gut microbiota and CVD are prominent.

Recent studies have found a link between gut microbiota, the microorganisms in human digestive tracts, and, CVD which is the leading cause of mortality worldwide. Gut microbiota is highly variable between individuals, and differences in gut microbial compositions between people with and without CVD have been reported.

Scientists at the University of Toledo (Toledo, OH, USA) hypothesized that machine learning (ML) could be used for gut microbiome–based diagnostic screening of CVD. To test their hypothesis, fecal 16S ribosomal RNA sequencing data of 478 CVD and 473 non-CVD human subjects collected through the American Gut Project were analyzed using five supervised ML algorithms, including random forest, support vector machine, decision tree, elastic net, and neural networks.

The team identified 39 differential bacterial taxa between the CVD and non-CVD groups. ML modeling using these taxonomic features achieved a testing area under the receiver operating characteristic curve (0.0, perfect antidiscrimination; 0.5, random guessing; 1.0, perfect discrimination) of ≈0.58 (random forest and neural networks). Next, the ML models were trained with the top 500 high-variance features of operational taxonomic units, instead of bacterial taxa, and an improved testing area under the receiver operating characteristic curves of ≈0.65 (random forest) was achieved.

Further, by limiting the selection to only the top 25 highly contributing operational taxonomic unit features, the area under the receiver operating characteristic curves was further significantly enhanced to ≈0.70. Among the bacteria identified were Bacteroides, Subdoligranulum, Clostridium, Megasphaera, Eubacterium, Veillonella, Acidaminococcus and Listeria were more abundant in the CVD group. Faecalibacterium, Ruminococcus, Proteus, Lachnospira, Brevundimonas, Alistipes and Neisseria were more abundant in the non-CVD group.

Bina Joe, PhD, FAHA, Distinguished University Professor and Chairwoman of the department of Physiology and Pharmacology, said, “Despite the fact that gut microbiomes are highly variable among individuals, we were surprised by the promising level of accuracy obtained from these preliminary results, which indicate fecal microbiota composition could potentially serve as a convenient diagnostic screening method for CVD.”

The authors concluded that overall, the study was the first to identify dysbiosis of gut microbiota in CVD patients as a group and apply this knowledge to develop a gut microbiome–based ML approach for diagnostic screening of CVD. The study was published on September 10, 2020 in the journal Hypertension.

Related Links:
University of Toledo


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.